Intratubular light chain amyloidosis: a comprehensive analysis of disease spectrum and clinicopathological
Xiaoyu Wang1, Yuxuan Yuan1, Dan Zhou1
1National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background:
The disease spectrum of intratubular light chain amyloidosis (AL) remains unknown.
Methods:
Patients with intratubular AL from a single center were retrospectively analyzed and stratified into three groups: Group 1, complicated by extra-tubular AL; Group 2, complicated by light chain cast nephropathy (LCCN); and Group 3, isolated intratubular AL. Clinical features, pathological findings, treatment regimens, and renal prognosis were compared across the groups.
Results:
The cohort (126 patients) was predominantly male (65.1%), with a mean age of 57 years and a high prevalence of the λ-light chain (78.6%). Group 1 was characterized by the lowest serum creatinine (Scr) and albumin, but the highest urinary protein and prevalence of systemic AL (all P < .05). Group 2 presented with higher Scr, prevalence of anemia and multiple myeloma (MM), elevated involved-to-uninvolved light chain ratio, and increased density of amyloid casts compared with Group 1 (all P < .05). Group 3 displayed similar hematological parameters and amyloid cast density as Group 1, with one patient displaying extrarenal AL. Overall, the hematological response rate was 54.3% and the renal remission rate was 26.4%. One patient in Group 3 progressed to MM. Group 2 had the highest incidence of end-stage renal disease (P < .05). Multivariate analysis identified Scr at biopsy as an independent predictor of renal prognosis.
Conclusion:
Intratubular AL is frequently identified in patients with renal AL and LCCN, presenting with characteristics associated with these two disorders. Isolated intratubular AL could progress to MM or systemic AL, thereby necessitating vigilant clinical monitoring.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Microtubules in Signaling
Lysosomal Hydrolases
Alzheimer Disease ll: Pathophysiology


